DM

Showing posts with label Report. Show all posts
Showing posts with label Report. Show all posts

Sunday, August 18, 2013

Top Hospitals Fall Flat in New Report

Consumer Reports said some of the nation's top hospitals performed the worst when it came to patient outcomes.

Massachusetts General Hospital and the Hospital for Special Surgeries, which are both ranked top in the nation for various specialties by U.S. News and World Report, got the lowest Consumer Reports Rating possible: a solid black circle.

But some doctors have questioned the way the ratings were determined.

Using hospital billing data from nearly 2,500 hospitals, Consumer Reports used length of hospital stay after surgery as an indicator of patient well-being to determine who would get its coveted solid red circle – Consumer Reports' highest rating. But many doctors said they were wary of whether this was the best way to rate hospitals. Even a Consumer Reports researcher said she did a double-take when she saw the results.

Length of hospital stay was gleaned from Medicare billing data rather than from patients' charts, and was considered an indicator of other complications. In other words, if a patient stayed in the hospital longer than what was expected for a particular surgery, researchers determined that he or she was more likely to have experienced complications.

Even if length of hospital stay was a good indicator for how well a patient fared after surgery, some doctors pointed out that certain hospitals routinely received more complex cases than others, leading to longer hospital stays. This would skew their Consumer Reports ratings, they said, punishing them for taking the tough cases.

"The problem I have with this is that teaching hospitals, which did poorly in this report, tend to have more complicated patients," said Dr. Richard Besser, chief health medical editor for ABC News. "More complicated patients will tend to be in the hospital longer. Community hospitals, which did better in this report, often refer their more complicated cases elsewhere."

Read about how hospital closures stress the health system.

The Massachusetts Hospital Association criticized the report in a statement.

"Consumer Reports' continued efforts to rate U.S. hospitals result in greater confusion rather than clarity with an oversimplification of this extremely complex and important subject."

When Consumer Reports researcher Doris Peter first saw the top hospitals performing poorly on her list, she said she asked her colleagues to take another look at the data. She said they stood by the data.

"It's not perfect," she said. "There are things that are just not in billing data that are in the clinical record."

Guess which hospitals are prescribing fruits and veggies.

The Hospital for Special Surgery in New York, for example, takes difficult cases from other hospitals, said hospital spokeswoman Shelley Rosenstock. She said Consumer Reports didn't differentiate between the different kinds of hip-replacement surgeries, which vary in difficulty and length of hospital stay.

Peter said Consumer Reports tried to get clinical data, but groups that collect it would not provide it. Since billing data often has flaws when it comes to reporting surgical complications, Consumer Reports' researchers used the length of stay data, and adjusted it to account for hospitals that had more complicated cases and searched for outliers.

"It's the best we can do with billing data," she said.

Cleveland Clinic's rating was another surprise on the list. It is nationally ranked in 14 specialties by U.S. News and World Report, but it came away with a mediocre rating on the Consumer Reports list.

Dr. Michael Henderson, chief quality officer at the Cleveland Clinic, said using billing data wasn't a good indicator of patient complications.

"Most surgical complications occur after patients leave the hospital," Henderson said.

Although most patients leave the hospital three or four days after surgery, most complications arise seven to 10 days later, he said. As such, administrative billing data, which is what Consumer Reports used, misses 61 percent of complications, Henderson said, referring to a study by the American College of Surgeons National Surgical Quality Improvement Program.

"I actually think that of the data sets, this is one of the weakest," he said. "We are in the middle, which is not terribly surprising because, again, we do get a lot of complications. There's some risk adjustment, but I don't think this methodology is very rigorous in its risk adjustment."

Peter said Consumer Reports may use readmission data the next time it does it's hospital ratings.

"Right now, it was too much for us to do all at once," she said. "We'll start with this measure and ideally pair it with a readmission measure."

Still, NYU Langone Medical Center, which is also nationally ranked by U.S. News and World Report, got the best possible rating: a solid red circle.

You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.

View the original article here

Sunday, July 7, 2013

Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target

Main Category: Cancer / Oncology
Also Included In: Biology / Biochemistry;??Genetics
Article Date: 03 Jul 2013 - 1:00 PDT Current ratings for:
Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target
2 starsnot yet rated
There's not much difference between what makes a man and what makes his beer - at least at the molecular level - according to a new study led by Professor John Schwabe at the University of Leicester.

Scientists used a powerful technique called protein crystallography to look at 3D structures of protein complexes purified from cultured human cells. They discovered that a family of complexes, that switch off gene expression, is regulated by small signalling molecules called inositol phosphates.

This latest study shows that this mode of regulation is conserved from yeast right through to man and is a fundamental process for life.

This discovery is potentially important for developing anti-cancer drugs since these complexes are emerging as effective cancer treatment targets.

The research was funded by the Wellcome Trust and involved collaboration with scientists from the University of Oxford. It was published online ahead of print (July 11) in the journal Molecular Cell.

The importance of this work is emphasised by the award, in November 2012, of £2.4 million in the form of a prestigious "Wellcome Trust Senior Investigator Award" to Professor John Schwabe to continue and develop this area of research.

Professor Schwabe said: "Gene regulation is an essential biological process that occurs in every cell in the body to control which proteins are expressed in particular tissues. We have been studying enzymes called Histone Deacetylases (HDACs) that regulate this process. The action of HDACs causes the DNA to become more tightly packaged and thus switches off genes by making them unavailable for expression. HDACs are recruited to DNA by a number of accessory proteins (corepressors) that target the enzyme to the correct gene."

In 2012, the research team announced in Nature that they had discovered a completely new and unexpected mechanism through which one particular HDAC complex (HDAC3 bound to its companion protein SMRT) is regulated.

Professor Schwabe said: "We wanted to ask whether this mode of regulation might apply to other HDAC complexes and be a general principle for HDAC regulation. Now we have taken this investigation several steps forward.

"We have solved the first structure of HDAC1 bound to one of its corepressor proteins (MTA1 - Metastasis-associated protein 1). This new structure allows us to examine how the proteins interact at the atomic level and reveals molecular details that have allowed us to probe the interaction surface.

"We have identified that there is an inositol phosphate-binding site at the interface between the two proteins, and through functional studies, we have confirmed that inositol phosphates are key regulators throughout this class of enzyme.

"This establishes that inositol phosphate regulation is a general paradigm that is conserved from yeast to man. In addition, we have shown that two MTA1 molecules come together to recruit two HDAC enzymes, and we suggest that MTA1 is critical for recruiting HDAC1 to DNA."

Professor Schwabe also emphasised that his research team is very privileged to have secured further funding from the Wellcome Trust to support this programme of research for the next 7 years: "We expect to gain an in depth insight into the role of inositol phosphates in the regulation of class I histone deacetylases and the specificity conferred to histone deacetylases by their recruitment into large multi protein complexes".

The research team used a cutting edge technique (protein crystallography) to look at the 3D structure of proteins involved in gene regulation. They optimised the conditions needed to grow microcrystals and took these to the UK's powerful synchrotron (Diamond Light Source, Oxford) to obtain diffraction data. These data are used to build images of the proteins, and for the first time, the team has been able analyse how the proteins interact with each other.

"With this new level of molecular detail we are exploring the design of novel HDAC inhibitors to target of the HDAC-corepressor interface. These may provide the foundation for future drug development and may lead to new anti-cancer therapies".

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. The University of Leicester team consisted of: Dr. Chris Millard, Dr. Peter Watson, Dr. Louise Fairall and Professor John Schwabe at the Biochemistry Department. The research involved a collaboration with Professor Dame Carol Robinson and Dr. Yuliya Gordiyenko at the Chemistry Department, University of Oxford.

University of Leicester

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Leicester. "Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target." Medical News Today. MediLexicon, Intl., 3 Jul. 2013. Web.
5 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Research Report Breakthrough In The Regulation Of A Key Cancer Drug Target'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here